CTOs on the Move

Harmony Biosciences

www.harmonybiosciences.com

 
Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to develop and commercialize novel treatment options for people living with rare diseases. With a focus on the central nervous system, including disorders of sleep and wakefulness, Harmony Biosciences is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurologic disorder.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tram Dang
 Director, Information Technology & Support Services Profile
Dan Weston
 Director, Information Technology PMO Profile

Funding

Harmony Biosciences raised $270M on 10/06/2017
Harmony Biosciences raised $200M on 01/27/2020

Similar Companies

ChemDiv

ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Odyssey Research Services

Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLink Life Sciences

BioLink Life Sciences is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tidal Vision

Chitosan manufacturer and supplier of ready-to-use chitosan flocculants, textile treatments, and agricultural elicitor applications.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.